Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026 
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
Baidu Shares Surge as Company Plans Kunlunxin AI Chip Spin-Off and Hong Kong Listing 
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
NEW YORK, March 09, 2017 -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that a conference call will be held tomorrow, Friday, March 10, 2017 at 8:30am ET to discuss results for the fourth quarter and year-end 2016, and provide a business outlook for 2017. Michael S. Weiss, Executive Chairman and Chief Executive Officer, will host the call.
In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics Year-End 2016 Earnings Call. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com. An audio recording of the conference call will also be available for replay at www.tgtherapeutics.com, for a period of 30 days after the call.
TG Therapeutics will announce its financial results for this period in a press release to be issued prior to the call.
ABOUT TG THERAPEUTICS, INC.
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies and autoimmune diseases. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B‐lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies, with TG-1101 also in clinical development for autoimmune disorders. The Company also has pre-clinical programs to develop IRAK4 inhibitors, BET inhibitors, and anti-PD-L1 and anti-GITR antibodies. TG Therapeutics is headquartered in New York City.
TGTX-G
Contact Jenna Bosco Vice President, Investor Relations TG Therapeutics, Inc. Telephone: 212.554.4351 Email: [email protected]
